Wolverine Trading’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$2.21M Sell
42,600
-3,500
-8% -$171K ﹤0.01% 2086
2025
Q2
$2.07M Sell
46,100
-900
-2% -$32.7K ﹤0.01% 1684
2025
Q1
$1.65M Sell
47,000
-16,300
-26% -$550K ﹤0.01% 1778
2024
Q4
$1.73M Buy
63,300
+19,600
+45% +$507K ﹤0.01% 2091
2024
Q3
$1.09M Sell
43,700
-15,900
-27% -$417K ﹤0.01% 2262
2024
Q2
$1.51M Sell
59,600
-7,700
-11% -$211K ﹤0.01% 1811
2024
Q1
$2.08M Buy
67,300
+46,400
+222% +$1.58M ﹤0.01% 1584
2023
Q4
$844K Sell
20,900
-12,800
-38% -$384K ﹤0.01% 2458
2023
Q3
$889K Sell
33,700
-44,700
-57% -$1.27M ﹤0.01% 2206
2023
Q2
$1.33M Sell
78,400
-67,300
-46% -$1.01M ﹤0.01% 1782
2023
Q1
$2.5M Buy
145,700
+121,200
+495% +$1.41M ﹤0.01% 1227
2022
Q4
$187K Buy
+24,500
New +$235K ﹤0.01% 3180
2022
Q2
Sell
-14,200
Closed -$147K 4497
2022
Q1
$147K Sell
14,200
-21,300
-60% -$219K ﹤0.01% 4624
2021
Q4
$517K Buy
35,500
+4,600
+15% +$195K ﹤0.01% 3409
2021
Q3
$1.47M Buy
30,900
+5,600
+22% +$300K ﹤0.01% 2510
2021
Q2
$1.52M Buy
+25,300
New +$1.44M ﹤0.01% 2272

Other funds holding BBIO

Wolverine Trading's BBIO Position: Q3 2025 in Review

Wolverine Trading increased its BridgeBio Pharma (BBIO) stake by 50% in Q3 2025, buying an estimated $808K and bringing the position to 49,886 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1950.

Wolverine Trading first reported a position in BBIO in Q1 2021 and has held it in 10 quarters since. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Wolverine Trading held 49,886 shares of BridgeBio Pharma worth $2.59M as of Q3 2025.
  • Wolverine Trading bought 16,564 BridgeBio Pharma shares in Q3 2025, an estimated $808K.
  • BridgeBio Pharma made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1950 holding.
  • Wolverine Trading first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 10 quarters since.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.